Biofrontera Inc. Announces Record Preliminary Q4 2025 Revenues, Exceeding $17M with Strong YOY Growth
BFRI sits 46% above its 52-week low of $0.536 on elevated volume (2.2× avg).
Summary
Biofrontera Inc. announced preliminary record revenues for the fourth quarter of 2025, ranging from $17.0 million to $17.5 million, alongside strong double-digit full-year growth.
Key Events · Earnings and Guidance · BFRI
-
Record Quarterly Revenue
Preliminary unaudited revenues for Q4 2025 are projected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the company's history.
-
Strong Year-Over-Year Growth
The Q4 2025 revenue figures reflect approximately 35% to 39% year-over-year growth, primarily driven by sales execution of Ameluz®.
-
Positive Full-Year Performance
Full year 2025 revenues are expected to be in the range of $41.5 million to $42.0 million, indicating double-digit growth of 11% to 13% year-over-year.
-
Strategic Foundation Strengthened
Management noted that a recent transformational transaction with Biofrontera AG is expected to meaningfully improve the gross margin profile and strengthen the financial foundation.
Analysis · BFRI · Life Sciences
Biofrontera Inc. reported preliminary unaudited revenues for Q4 2025 between $17.0 million and $17.5 million, marking the highest quarterly revenue in the company's history. This represents significant year-over-year growth of approximately 35% to 39%. For a company with a market capitalization of under $10 million, these revenue figures are exceptionally strong and indicate robust operational performance. The CEO highlighted strong execution, continued growth of Ameluz® PDT, and a recent transformational transaction with Biofrontera AG that is expected to improve gross margin and strengthen the financial foundation. This positive update could significantly re-rate the company's valuation and investment thesis.
At the time of this filing, BFRI was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.54 to $1.24. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.